Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 17/20 | 0.74 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.74 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.62 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311310 | 1.00 | PTGER2 (0.74) | PTGER2PTGER3PTGDRPTGER4TBXA2R | |
| SCHEMBL12112053 | 0.93 | PTGER2 (0.67) | PTGER2PTGER3PTGDRPTGER4NR1H4 | |
| SCHEMBL14358803 | 0.93 | PTGER2 (0.67) | PTGER2PTGER3PTGDRPTGER4NR1H4 | |
| SCHEMBL13667628 | 0.87 | PTGER2 (0.57) | PTGER2PTGER3PTGDRPTGER4MEN1 | |
| SCHEMBL1310059 | 0.85 | PTGER2 (1.00) | PTGER2PTGER3PTGDRPTGER4TBXA2R | |
| SCHEMBL1310058 | 0.85 | PTGER2 (1.00) | PTGER2PTGER3PTGDRPTGER4TBXA2R | |
| SCHEMBL2992422 | 0.85 | PTGER2 (1.00) | PTGER2PTGER3PTGDRPTGER4TBXA2R | |
| SCHEMBL13823435 | 0.84 | PTGER2 (0.53) | PTGER2PTGER3PTGDRPTGER4 | |
| SCHEMBL13181248 | 0.84 | PTGER2 (0.53) | PTGER2PTGER3PTGDRPTGER4 | |
| SCHEMBL13385600 | 0.79 | PTGER2 (0.69) | PTGER2PTGER3PTGDRTBXA2RNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550502-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2009-06-23 | — | — | US | claimed |
| EP-1996546-B1 | SUBSTITUTED GAMMA LACTAMS AS PROSTAGLANDIN EP2 AGONISTS | ALLERGAN INC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-7781482-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781482-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781482-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090227653-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227653-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227653-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550502-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550502-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2007109578-A2 | SUBSTITUTED GAMMA LACTAMS AS PROSTAGLANDIN EP2 AGONISTS | ALLERGAN, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227653-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | PTGER2 3210/4885PTGER3 2745/4885PTGDR 1340/4885 |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | PTGER2 3210/4885PTGER3 2745/4885PTGDR 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.